A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma

被引：9

作者：

Ohgami, Masahiro ^{[1
,2
]}

Homma, Masato ^{[1
,3
]}

Suzuki, Yoshiharu

Naito, Kanako ^{[2
]}

Yamada, Motoko ^{[2
]}

Mitsuhashi, Shoichi ^{[4
]}

Fujisawa, Fumie ^{[4
]}

Kojima, Hiroshi ^{[4
]}

Kaburagi, Takayuki ^{[5
]}

Uchiumi, Keiko ^{[5
]}

Yamada, Yutaka ^{[5
]}

Bando, Hiroko ^{[6
]}

Hara, Hisato ^{[5
]}

Takei, Keiji ^{[2
]}

机构：

[1] Univ Tsukuba, Dept Pharmaceut Sci, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan

[2] Ibaraki Cent Hosp, Dept Pharm, Kasama, Ibaraki, Japan

[3] Univ Tsukuba Hosp, Dept Pharm, Tsukuba, Ibaraki, Japan

[4] Ibaraki Cent Hosp, Dept Med Oncol, Kasama, Ibaraki, Japan

[5] Ibaraki Cent Hosp, Dept Resp Med, Kasama, Ibaraki, Japan

[6] Univ Tsukuba, Dept Breast & Endocrine Surg, Tsukuba, Ibaraki, Japan

来源：

THERAPEUTIC DRUG MONITORING | 2016年 / 38卷 / 06期

关键词：

HPLC; lapatinib; erlotinib; therapeutic drug monitoring; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; TANDEM MASS-SPECTROMETRY; BREAST-CANCER; OPEN-LABEL; 1ST-LINE TREATMENT; PHASE-I; EGFR; PHARMACOKINETICS; QUANTIFICATION;

D O I：

10.1097/FTD.00000000000003520

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Background: Lapatinib and erlotinib are used for cancer treatment, showing large interindividual variability. Therapeutic drug monitoring may be useful for assessing the clinical outcomes and adverse events. A simple high-performance liquid chromatography UV method was developed for the determination of lapatinib and erlotinib in human plasma. Methods: An aliquot of plasma sample spiked with internal standard was treated with acetonitrile to precipitate the proteins. Lapatinib and erlotinib were separated on an octadecylsilyl silica gel column using a mobile phase consisting of acetonitrile, methanol, water, and trifluoroacetic acid (26:26:48:0.1) pumped at a flow rate of 1.0 mL/min. The detection wavelength was set at 316 nm. Results: The calibration curves for lapatinib and erlotinib were linear (r = 0.9999) in the range of 0.125-8.00 mcg/mL. The extraction recoveries for both lapatinib and erlotinib at the plasma concentration of 0.125-8.00 mcg/mL were higher than 89.9% with coefficients of variation less than 3.5%. The coefficients of variation for intraday and interday assays of lapatinib and erlotinib were less than 5.1% and 6.1%, respectively. Conclusions: The present method can be used for blood concentration monitoring for lapatinib or erlotinib in exactly the same conditions.

引用

页码：657 / 662

页数：6

共 24 条

[1] Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS [J].